Immutep (ASX:IMM) Float Percentage Of Total Shares Outstanding: 97.36% (As of Jun. 29, 2026)


What is Immutep Float Percentage Of Total Shares Outstanding?

Immutep ASX:IMM -5.88% Float Percentage Of Total Shares Outstanding is 97.36% as of Jun. 29, 2026. The stock has 1 warning sign investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immutep's float shares is 1,434.75 Mil. Immutep's total shares outstanding is 1,473.72 Mil. Immutep's float percentage of total shares outstanding is 97.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immutep's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immutep's Institutional Ownership is 9.62%.

Immutep Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Immutep's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=1,434.75/1,473.72
=97.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 97.36% mean?
Immutep (ASX:IMM) has a Float Percentage Of Total Shares Outstanding of 97.36% as of Jun. 29, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Immutep and its competitors.
Is Immutep's Float Percentage Of Total Shares Outstanding too high?
Immutep's current Float Percentage Of Total Shares Outstanding is 97.36%.
How does Immutep's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Immutep's Float Percentage Of Total Shares Outstanding of 97.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Immutep and its competitors. Immutep's current Float Percentage Of Total Shares Outstanding is 97.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (ASX:IMM) has a current Float Percentage Of Total Shares Outstanding of 97.36%. The current Float Percentage Of Total Shares Outstanding is 97.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Immutep (ASX:IMM), the current Float Percentage Of Total Shares Outstanding is 97.36% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.